CYDY has ALWAYS BEEN UNBLINDED on CD12?!?!?!? That post

New Post Public Reply Private Reply Replies (1) Message Board
havasu78 Enjay #72086
770
CYDY has ALWAYS BEEN UNBLINDED on CD12?!?!?!?

That post is way beyond an "interesting read".

That post is an unequivocal claim that CYDY has always known the results of the CD12 trial in real time as they have developed.

If true, every comment and action by Pourhassan must be re-examined in light of the possiblity that Pourhassan and possibly every other CYDY employee knows the CD12 primary endpoint progress and has known this progress from the first day the first CD12 patient was dosed.

"Knowing the results" is not quite the same thing as "unblinded", but as a practical matter there absolutely is no difference if I am a CYDY employee who wants to know how CD12 is progressing.

There are only three predicates, the first two claimed by Science+Compliance as facts, upon which the claim that CYDY has always known real-time CD12 results:

1) A file named eTMF exists and that file includes the medical records of CD12 patients.

2) Someone at CYDY can open that file and review the medical records.

3) Pourhassan elected to review the eTMF file and the CD12 results it provides.

Can anyone comment on whether these predicates are possible? Is there really such thing as an eTMF file? Does it include all of the CD12 patient medical records, including blood test results?

Finally, and most importantly, who at CYDY is allowed to access the eTMF and are they allowed to publicly reveal what they learned from the eTMF?

A serious deficit in Science+Compliance's analysis is that he does not understand leronlimab and CCR5.

CCR5 receptor occupancy, which is performed on all CD12 patients, distinguishes between leronlimab and placebo arms with 100% accuracy. Science+Compliance discusses RANTES, bilirubin and others in the context of whether or not the medical records can indicate LL or placebo, but none of those are relevant. CCR5 receptor occupancy is 100% dispositiv of who got LL and who is on placebo.

So if there exists an electronic file that contains medical records for all CD12 patients, and if that file is accessible to CYDY employees, then anyone at CYDY interested to look can see the CD12 progress in real time.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

York Space Systems Faces Lawsuit Over IPO Debacle

Updated Category News Views 2

Trouble Brewing in York Space Systems' Orbit Here's the nitty-gritty: York Space Systems (NYSE: YSS)—a company's whose bread was buttered primarily by Uncle Sam—is now facing some serious heat. We're talking about allegations that make you double-check your portfolio and rethink that second helping of whatever Wall Street's serving. The Stakes: From Space to Legal...

Continue Reading
Blue Light Glasses: Beyond The Hype? A Deep Dive

Updated Category News Views 1

Blue Light Glasses: Useful or Just a Fad? Listen, these blue light glasses have stirred quite the buzz lately. As screen times shoot through the roof in every nook and cranny of our lives—schools, workplaces, and even our downtime—the question grows more pressing: Are these glasses the real deal or just another gimmick? Unpacking the Myths with Andrea Hill Andrea Hill...

Continue Reading
SecondSideMedia Tackles AI Misinformation with New Platform

Updated Category News Views 3

Overcoming the AI Misinformation Maze The AI revolution isn't without its hiccups, and when machines spin their tales wrong, damage control becomes a necessity. Enter SecondSideMedia, coming out swinging with a platform specifically crafted to tackle those pesky inaccuracies AI can spit out. They launched this beauty after a successful pilot and they aren't following the...

Continue Reading
Manulife's $750M US Offering: Risky or Strategic?

Updated Category News Views 1

Manulife: Debuting $750M in Subordinated Notes When it comes to Manulife's latest move, it's all about the numbers. They've priced a U.S. public offering of a meaty $750 million in subordinated notes at an enticing 6.146% interest rate. That's no pocket change, folks, and it highlights a strategy or a gamble, depending on your view. But here's the kicker: these notes may...

Continue Reading
Medtronic's Q1 2027 Surge Signals Promising Future

Updated Category News Views 2

Medtronic's Impressive Q1 2027: A Closer Look It's not every day you see a healthcare titan like Medtronic (NYSE: MDT) flex some serious muscle on the financial front. As the first quarter of fiscal year 2027 wrapped up, Medtronic delivered a knockout with a reported 13.7% increase in revenue, totaling a hefty $9.8 billion. This wasn't just luck—this was strategic...

Continue Reading
Hycroft Overhauls Board with Mining Heavyweights

Updated Category News Views 1

High-Caliber Recruits Steer Hycroft's Ambitious Path Hycroft Mining's move to bulk up its board ought to raise eyebrows across the mining landscape. By snagging some of the biggest names in the industry, they're not just shuffling the deck—they're bringing in a whole new game plan. If you're tracking NASDAQ:HYMC, this is news you don't brush off. The New Power Quartet...

Continue Reading
Kareem's Lebanese Kitchen: A Culinary Tribute to Maryland

Updated Category News Views 2

Embracing Tradition with a Modern Twist Well, here's to new beginnings wrapped in old flavors, folks. September 1, 2026, marks the arrival of Kareem's Lebanese Kitchen at Rio Lakefront in Gaithersburg, Maryland. It's where the Mediterranean meets the Chesapeake in an unexpected culinary celebration. Chef Rachid Eido's Legacy Third-generation Lebanese Chef Rachid Eido is...

Continue Reading
2026 Mighty 25: Celebrating Military Community Leaders

Updated Category News Views 1

A Spotlight on Unsung Heroes Tampa, Florida, just got a little mightier as We Are The Mighty rolls out the red carpet for the 2026 Mighty 25. This annual roll call, backed by CareSource Military & Veterans™, shines a light on veterans, military spouses, creators, entrepreneurs, and change agents defying the status quo. They are redefining impact across the military...

Continue Reading
Medtronic's $80M Bet: Pi-Cardia's Heart Tech

Updated Category News Views 2

Medtronic's Calculated Leap with Pi-Cardia Just when you think the world of healthcare technology quiets down, here comes Medtronic (NYSE: MDT) barreling in with a hefty $80 million strategic play in Pi-Cardia Ltd. This move is no mere feather in the cap; it’s a calculated maneuver to refresh and supercharge their structural heart portfolio. What are they really gunning...

Continue Reading
ARC Rescues 86 Dogs: A Hopeful Path to Recovery

Updated Category News Views 4

Turning the Tides for Canine Lives Hope came with the lunar eclipse for a group of dogs in Missouri. Thanks to the Operation Eclipse, led by the Animal Rescue Corps (ARC), 86 dogs and two kittens found a ray of hope. The peculiar alignment in the sky seemed a fitting backdrop for the newfound beginning these animals desperately needed. Let's dive right into what unfolded...

Continue Reading

Top 5 Most Recently Viewed Articles

Spectral Medical Updates on Tigris Trial and Company Progress

Updated Category News Views 170

Spectral Medical Advances Tigris Trial and Financial Insights Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), an innovative late-stage theranostic company, is on a significant journey as it works toward advancing treatment options for sepsis and septic shock. In a recent announcement, Spectral shared updates on their financial performance and...

Continue Reading
Performance Peterbilt Joins The Larson Group in Strategic Deal

Updated Category News Views 203

Performance Peterbilt Transitions to The Larson Group Performance Brokerage Services, recognized for its expertise in dealership buy-sell transactions, has successfully facilitated the transition of Performance Peterbilt to The Larson Group, encompassing eight locations across several states. This strategic move is anticipated to enhance the operational capabilities and...

Continue Reading
How a $1000 Investment in TSM a Decade Ago Would Pay Off

Updated Category News Views 178

A Decade of Growth for Taiwan Semiconductor Taiwan Semiconductor (NASDAQ: TSM) has established a remarkable performance record over the past decade. Investors who placed their trust in TSM have seen an impressive annualized return of 25.44%. This rate is significantly higher than the general market, which has made TSM a standout option for those looking to build wealth...

Continue Reading
Amplix Acquisition of OneConnect Expands Tech Arsenal

Updated Category News Views 8

Amplix's Strategic Move to Bolster Tech Services Right, let’s get into it. Amplix, backed by Gemspring Capital and already doing a pretty solid job in the tech advisory space, just added another feather to its cap. They’ve snapped up OneConnect, making this the fifteenth company they’ve absorbed since building their platform in 2022. No surprise here—they’re...

Continue Reading
Bridging the Technological Divide: Insights from Omnia's Report

Updated Category News Views 118

Significant Findings from the Latest Technology Impact Analysis In a world where technology continues to evolve rapidly, a recent report highlights the critical disparities between ambition and readiness among organizations. Omnia Strategy Group has published its 2025 Technology Impact Report, which examines the current landscape of technology and its implications for...

Continue Reading